Publications by authors named "Mikhail Rojavin"

Claim this Profile
A
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
Richard J Nowak, Michael Benatar, Emma Ciafaloni, James F Howard, M Isabel Leite, Mikhail Rojavin

N Engl J Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic IgG exposure and safety in patients with primary immunodeficiency: a randomized crossover study comparing a novel investigational wearable infusor versus the Crono pump.
Richard L Wasserman, Charlotte Cunningham-Rundles, John Anderson, Patricia Lugar, Michael Palumbo, Mikhail A Rojavin

Immunotherapy· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of IgPro10 in Japanese primary immunodeficiency patients: a registrational study.
Tomohiro Morio, Kenji Gotoh, Tomoyuki Imagawa, Kimio Morita, Hidenori Ohnishi, Mikhail A Rojavin

Int J Hematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study.
John T Anderson, Vincent R Bonagura, Juthaporn Cowan, Connie Hsu, S Shahzad Mustafa, Mikhail A Rojavin

J Clin Immunol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study.
Juthaporn Cowan, Vincent R Bonagura, Patricia L Lugar, Paul J Maglione, Niraj C Patel, Mikhail A Rojavin

J Clin Immunol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency.
Mikhail A Rojavin, Hugo Chapdelaine, Michael A Tortorici, Michaela Praus, Gautam Baheti

Clin Pharmacol Drug Dev· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra®) dosing in patients with primary immunodeficiency.
Ying Zhang, Gautam Baheti, Hugo Chapdelaine, Jutta Hofmann, Mikhail Rojavin

Int Immunopharmacol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacometric Analysis of IgPro10 in Japanese and Non-Japanese Patients With Primary Immunodeficiency.
Dandan Luo, Gautam Baheti, Michael A Tortorici, Jutta Hofmann, Mikhail A Rojavin

Clin Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic properties of Privigen in Japanese patients with primary immunodeficiency.
Tomohiro Morio, Gautam Baheti, Michael A Tortorici, Jutta Hofmann, Mikhail A Rojavin

Immunol Med· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients.
Paula Busse, James Baker, Inmaculada Martinez-Saguer, Jonathan A Bernstein, Timothy Craig, Mikhail Rojavin

J Allergy Clin Immunol Pract· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
Michael A Tortorici, John-Philip Lawo, Rudolf Weide, Jeanine Jochems, Shilpa Puli, Mikhail A Rojavin

Int Immunopharmacol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
Stephen Jolles, Mikhail A Rojavin, John-Philip Lawo, Robert Nelson, Richard L Wasserman

J Clin Immunol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies.
Rajiv Mallick, Stephen Jolles, Hirokazu Kanegane, Dominique Agbor-Tarh, Mikhail Rojavin

J Clin Immunol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data.
Marc A Riedl, Anette Bygum, William Lumry, Markus Magerl, Jonathan A Bernstein, Mikhail Rojavin

J Allergy Clin Immunol Pract· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema.
James Fox, Arthur B Vegh, Inmaculada Martinez-Saguer, Walter A Wuillemin, Jonathan Edelman, Mikhail Rojavin

Allergy Asthma Proc· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema.
Timothy Craig, Ralph Shapiro, Arthur Vegh, James W Baker, Jonathan A Bernstein, Mikhail Rojavin

Allergy Rhinol (Providence)· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry.
Markus Magerl, Michael Frank, William Lumry, Jonathan Bernstein, Paula Busse, Mikhail Rojavin

Ann Allergy Asthma Immunol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of a C1 Inhibitor Concentrate in Adults ≥65 Years of Age with Hereditary Angioedema: Findings from the International Berinert (C1-INH) Registry.
Anette Bygum, Inmaculada Martinez-Saguer, Murat Bas, Jeffrey Rosch, Jonathan Edelman, Mikhail Rojavin

Drugs Aging· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor.
Henriette Farkas, Lilian Varga, Dumitru Moldovan, Krystyna Obtulowicz, Todor Shirov, Mikhail Rojavin

Ann Allergy Asthma Immunol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency.
Mikhail A Rojavin, Alphonse Hubsch, John-Philip Lawo

J Clin Immunol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of C1-esterase inhibitor in acute and prophylactic therapy of hereditary angioedema: findings from the ongoing international Berinert patient registry.
Paula Busse, Anette Bygum, Jonathan Edelman, William Lumry, Thomas Machnig, Mikhail Rojavin

J Allergy Clin Immunol Pract· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency.
Jagdev Sidhu, Mikhail Rojavin, Marc Pfister, Jonathan Edelman

Biol Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.
Morna J Dorsey, Viet Ho, Mohsen Mabudian, Pere Soler-Palacín, Nerea Domínguez-Pinilla, Mikhail Rojavin

J Clin Immunol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease.
Stephen Jolles, Michael Borte, Robert P Nelson, Mikhail Rojavin, Martin Bexon

Clin Immunol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
Hirokazu Kanegane, Kohsuke Imai, Masafumi Yamada, Hidetoshi Takada, Tadashi Ariga, Mikhail Rojavin

J Clin Immunol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis